Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKinsey
Argus Health
US Department of Justice
McKesson
Merck
Medtronic
Novartis
Chubb

Generated: October 23, 2017

DrugPatentWatch Database Preview

Iloperidone - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for iloperidone and what is the scope of iloperidone freedom to operate?

Iloperidone
is the generic ingredient in two branded drugs marketed by Inventia Hlthcare and Vanda Pharms Inc, and is included in two NDAs. There are ten patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Iloperidone has one hundred and eighty patent family members in thirty-one countries.

There are eight drug master file entries for iloperidone. Four suppliers are listed for this compound.

Summary for Generic Name: iloperidone

US Patents:10
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: see list8
Suppliers / Packagers: see list4
Bulk Api Vendors: see list77
Clinical Trials: see list17
Patent Applications: see list1,837
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:iloperidone at DailyMed

Pharmacology for Ingredient: iloperidone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Inventia Hlthcare
ILOPERIDONE
iloperidone
TABLET;ORAL207231-007Nov 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Inventia Hlthcare
ILOPERIDONE
iloperidone
TABLET;ORAL207231-003Nov 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: iloperidone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-001May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: iloperidone

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,580,887 1- (arylthioalkyl , arylaminoalkyl or arylmethylenealkyl) -4- (heteroaryl) piperidines and related compounds useful as anti-psychotics and analgesics► Subscribe
5,612,342 United States Patent: 5612342   ( 1► Subscribe
6,140,345 1-(aryloxyalkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics► Subscribe
5,599,821 4-heteroaryl-1-piperidinealkylamines and derivatives thereof and their therapeutic utility► Subscribe
5,663,449 Intermediate compounds in the synthesis of heteroarylpiperidines, pyrrolidines and piperazines► Subscribe
RE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics► Subscribe
5,580,875 1-[(2-pyrimidinyloxy)alkyl]-3-(heteroaryl)pyrrolidines and related compounds and therapeutic utility► Subscribe
5,589,495 2-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-1,3- indandiones and related compounds and their therapeutic utility► Subscribe
5,364,866 Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics► Subscribe
5,776,963 3-(heteroaryl)-1-[(2,3-dihydro-1h-isoindol-2-yl)alkyl]pyrrolidines and 3-(heteroaryl)-1-[(2,3-dihydro-1h-indol-1-yl)alkyl]pyrrolidines and related compounds and their therapeutic untility► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: iloperidone

Country Document Number Estimated Expiration
SloveniaEP2417267► Subscribe
Poland314135► Subscribe
Japan5653753► Subscribe
Germany69233686► Subscribe
Finland20100200► Subscribe
New Zealand233710► Subscribe
Greece3017447► Subscribe
China1048037► Subscribe
Hong Kong1023776► Subscribe
Australia2009291717► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
US Army
Cerilliant
Chinese Patent Office
Johnson and Johnson
Fish and Richardson
Colorcon
Citi
Medtronic
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot